KemPharm, Inc.
http://www.kempharm.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From KemPharm, Inc.
RhoVac Seeks Path Forward After Phase IIb Prostate Cancer Disappointment
Despite a seemingly sound mechanism and promising early data, the Swedish firm’s sole clinical asset has flunked a mid-stage prostate cancer trial, prompting a search for responsive subgroups.
Finance Watch: Biotech Stocks Stabilize At The End Of A Rocky Week
Public Company Edition: Valuations have fallen enough in 2022 to lead some companies to wind down operations, but a recent uptick opened a window for a few offerings. Chinook raised $105m in a follow-on offering, while Flagship led a $79.2m registered direct offering for Evelo.
Orphazyme’s Sorry Story Ends In Fire Sale
While Orphazyme's attempts to get approval for arimoclomol failed miserably, new owner KemPharm is confident it can get the oral heat shock protein amplifier across the regulatory finishing line for Niemann-Pick disease type C.
Finance Watch: More Job Cuts As Companies Prioritize Cash Conservation
Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools